All Comments by Benjamin Wolozin

  1. Presenting: A Not-Quite-Parkinson's Mouse Model
  2. Effects of environmental enrichment on gene expression in the brain.
  3. Presenilin-1 P264L knock-in mutation: differential effects on abeta production, amyloid deposition, and neuronal vulnerability.
  4. ASP1 (BACE2) cleaves the amyloid precursor protein at the beta-secretase site.
  5. Identification of ubiquilin, a novel presenilin interactor that increases presenilin protein accumulation.
  6. Domain homologues of dopamine beta-hydroxylase and ferric reductase: roles for iron metabolism in neurodegenerative disorders?
  7. The C-terminal fragment of the Alzheimer's disease amyloid protein precursor is degraded by a proteasome-dependent mechanism distinct from gamma-secretase.
  8. Estrogen lowers Alzheimer beta-amyloid generation by stimulating trans-Golgi network vesicle biogenesis.
  9. Interaction of human alpha-Synuclein and Parkinson's disease variants with phospholipids. Structural analysis using site-directed mutagenesis.
  10. Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain.
  11. Identification of genes that modify ataxin-1-induced neurodegeneration.
  12. Brain plasmin enhances APP alpha-cleavage and Abeta degradation and is reduced in Alzheimer's disease brains.
  13. Staging of neurofibrillary degeneration caused by human tau overexpression in a unique cellular model of human tauopathy.
  14. p35/cdk5 binds and phosphorylates beta-catenin and regulates beta-catenin/presenilin-1 interaction.
  15. Biochemical identification of the neutral endopeptidase family member responsible for the catabolism of amyloid beta peptide in the brain.